Argos Therapeutics to Host Investor Day on Wednesday, December 7, 2016
October 19 2016 - 8:00AM
Event to be held at NASDAQ MarketSite in New York
City from 8:00-11:00 a.m. Eastern Time.
Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology
company focused on the development and commercialization of
individualized immunotherapies based on the
Arcelis® technology platform, today announced that
the company will host an Investor Day on Wednesday, December 7,
2016 from 8:00-11:00 a.m. Eastern Time at NASDAQ MarketSite in New
York City.
Argos’ management will review the scientific, clinical and
commercial opportunity behind the company’s lead product candidate,
AGS-003, which is currently being evaluated in the
pivotal ADAPT Phase 3 clinical trial for the
treatment of advanced kidney cancer. Gerald Linette, MD, PhD, chief
medical officer for cancer immunotherapy at the University of
Pennsylvania Abramson Cancer Center, and Christopher Wood, MD,
FACS, professor of urology, division of surgery at the University
of Texas MD Anderson Cancer Center will join management in
discussing AGS-003 and the treatment
landscape.
Dr. Linette is an inaugural member of the Argos Scientific
Advisory Board (SAB) with a primary interest in human cancer
immunology. He also serves as diplomat of medical oncology for the
American Board of Internal Medicine, and clinical director for the
Parker Institute for Cancer Immunotherapy. Dr. Linette earned his
MD/PhD in microbiology from Georgetown University School of
Medicine.
Dr. Wood is a kidney cancer specialist and a member of the renal
cancer task force committee for the National Cancer Institute. He
also serves as a member of the American Urological Association
practice guidelines panel. Dr. Wood earned his MD from Northwestern
University Medical School.
NASDAQ MarketSite is the commercial marketing presence of the
NASDAQ stock market and is located in the Condé Nast Building at 4
Times Square. Argos Investor Day registration and webcast details
will be made available in the coming weeks. For more information on
the company, visit http://www.argostherapeutics.com/.
About the Arcelis® Technology
PlatformArcelis® is a precision
immunotherapy technology that captures both mutated and variant
antigens that are specific to each patient’s individual disease. It
is designed to overcome immunosuppression by producing a
specifically targeted, durable memory T-cell response without
adjuvants that may be associated with toxicity. The technology is
potentially applicable to the treatment of a wide range of
different cancers and infectious diseases, and is designed to
overcome many of the manufacturing and commercialization challenges
that have impeded other personalized immunotherapies. The
Arcelis® process uses only a small disease sample
or biopsy as the source of disease-specific antigens, and the
patient’s own dendritic cells, which are optimized from cells
collected by a single leukapheresis procedure. The proprietary
process uses RNA isolated from the patient's disease sample to
program dendritic cells to target disease-specific antigens. These
activated, antigen-loaded dendritic cells are then formulated with
the patient’s plasma, and administered via intradermal injection as
an individualized immunotherapy.
About Argos TherapeuticsArgos Therapeutics is
an immuno-oncology company focused on the development and
commercialization of individualized immunotherapies for the
treatment of cancer and infectious diseases using its
Arcelis® technology platform. Argos' most advanced
product candidate, AGS-003, is being evaluated in
the pivotal ADAPT Phase 3 clinical trial for the
treatment of metastatic renal cell carcinoma (mRCC). In
addition, AGS-003 is being studied in
Phase 2 investigator-initiated clinical trials as
neoadjuvant therapy for renal cell carcinoma (RCC) and for the
treatment of non-small cell lung cancer (NSCLC). Argos is also
developing a separate Arcelis®-based product
candidate, AGS-004, for the treatment of human
immunodeficiency virus (HIV), which is currently being evaluated in
an investigator-initiated Phase 2 clinical trial
aimed at HIV eradication in adult patients.
Forward Looking StatementsAny statements in
this press release about Argos’ future expectations, plans and
prospects, including statements about the expected and potential
future closings of the private placement, Argos’ financial
prospects, anticipated use of proceeds, future operations and
sufficiency of funds for future operations, clinical development of
Argos’ product candidates, expectations regarding future clinical
trials and future expectations and plans and prospects for Argos
and other statements containing the words "believes,"
"anticipates," "estimates," "expects," "intends," "plans,"
"predicts," "projects," "targets," “may,” "potential," "will,"
"would," "could," "should," "continue," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including whether Argos' cash resources will be sufficient
to fund its continuing operations for the periods anticipated;
whether results obtained in clinical trials will be indicative of
results obtained in future clinical trials; whether Argos' product
candidates will advance through the clinical trial process on a
timely basis; whether the results of such trials will warrant
submission for approval from the United States Food and Drug
Administration or equivalent foreign regulatory
agencies; whether Argos' product candidates will receive
approval from regulatory agencies on a timely basis or at all;
whether, if product candidates obtain approval, they will be
successfully distributed and marketed; and other factors discussed
in the "Risk Factors" section of Argos’ Form 10-Q for the quarter
ended June 30, 2016, which is on file with the SEC, and in
other filings Argos makes with the SEC from time to time. In
addition, the forward-looking statements included in this press
release represent Argos’ views as of the date hereof. Argos
anticipates that subsequent events and developments will cause
Argos’ views to change. However, while Argos may elect to update
these forward-looking statements at some point in the future, Argos
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Argos’ views as of any date subsequent to the date
hereof.
Media contact:
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com
Investor contact:
John Menditto
Argos Therapeutics, Inc.
919-908-0687
jmenditto@argostherapeutics.com